20 June 2013
Keywords: pfizer, aromasin, boosts, dfs, early, breast, cancer
Article | 22 December 2008
Pfizer's aromatase inhibitor Aromasin (exemestane) given to women with early breast cancer reduces the relative risk of disease recurrence
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 December 2008
19 June 2013
© 2013 thepharmaletter.com